A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OReO; OReO/ENGOT Ov-38
- Sponsors AstraZeneca
- 12 Sep 2017 Trial dsign presented at the 42nd European Society for Medical Oncology Congress.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.
- 29 May 2017 Planned initiation date changed from 28 Apr 2017 to 7 Jun 2017.